Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 25 clinical trials
Bevacizumab Combined With Gefitinib in the Treatment of Advanced NSCLC

To compare the efficacy and safety of gefitinib combined with bevacizumab and gefitinib in the treatment of L858R positive mutation in exon 21 of EGFR gene in advanced NSCLC.

  • 0 views
  • 25 Jan, 2021
  • 1 location
Gefitinib in Combination With Anlotinib or Placebo in Previously Untreated EGFR-mutant NSCLC (FL-ALTER)

Gefitinib is currently the standard-of-care for patients with activating-EGFR mutant advanced non-small cell lung cancer (NSCLC). However, ~30-40% patients are still nonresponsive, and

lung carcinoma
EGFR
targeted therapy
measurable disease
recurrent non-small cell lung cancer
  • 1 views
  • 17 Feb, 2022
A Study of Gefitinib With or Without Apatinib in Patients With Advanced Non-squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations

The main purpose of this study is to evaluate the safety and efficacy of Apatinib in combination with Gefitinib as compared to placebo in combination with Gefitinib in participants with stage B

  • 12 views
  • 24 Feb, 2022
  • 1 location
A Phase III Randomized Multi-center Study to Determine the Efficacy of the Intercalating Combination Treatment of Chemotherapy and Gefitinib or Chemotherapy as Adjuvant Treatment in NSCLC With Common EGFR Mutations.

This study aims to compare the efficacy of intercalating chemotherapy (gefitinib and pemetrexed/cisplatin) and chemotherapy (navelbine/cisplatin) in completely resected NSCLC with common EGFR

  • 0 views
  • 22 Jan, 2021
A Study of FWD1509 in Adults With Non-Small Cell Lung Cancer (FWD1509)

The purpose of this study is to characterize the safety and tolerability of FWD1509 MsOH in advanced NSCLC patients and establish the maximum tolerable dose (MTD), recommended phase 2 dose (RP2D) in advanced NSCLC patients.

measurable disease
neutrophil count
systemic therapy
lung carcinoma
kidney function test
  • 0 views
  • 19 Apr, 2022
  • 1 location
PDAC Peripheral and Portal Vein Sampling

This is a research study in which bio-specimens (whole blood, plasma and serum from peripheral circulation and portal vein) will be collected from patients with pancreatic adenocarcinoma for translational research. These samples will be used for (but not limited to) identification and characterisation of blood-borne biomarkers at the genomic and …

pdac
  • 0 views
  • 22 Mar, 2022
  • 2 locations
Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving INC280 Treatment as Single Agent or in Combination With Other Treatments.

Gefitinib in a Novartis sponsored study and in the opinion of the Investigator would benefit from continued treatment.

  • 16 views
  • 16 Mar, 2022
  • 6 locations
Gefitinib With or Without Chemotherapy in Brain Metastases From Non-small Cell Lung Cancer

This is a multi-center phase II randomized controlled study to assess the efficacy of Gefitinib alone and Gefitinib combinating with Pemetrexed/platinum on patients with brain metastasis from

lung carcinoma
cancer
lung cancer
icotinib
metastasis
  • 16 views
  • 13 Mar, 2022
Lenvatinib Combined With Gefitinib in the Treatment of Lenvatinib-resistant Hepatocellular Carcinoma

This is a prospective clinical study aiming to tests the safety and efficacy of lenvatinib in combination with gefitinib in people with lenvatinib resistant hepatocellular carcinoma. This study

  • 0 views
  • 29 Jan, 2021
  • 1 location
MEchanisms of Resistance in EGFR Mutated Nonpretreated Advanced Lung Cancer Receiving OSimErtib (MELROSE)

randomized phase 3 study clearly demonstrated the superiority of osimertinib compared with erlotinib or gefitinib in EGFR mutated nonpretreated NSCLC (median PFS of 18.9 months versus 10.2 months).

carcinoma
erlotinib
osimertinib
kinase inhibitor
epidermal growth factor receptor
  • 6 views
  • 08 Feb, 2022
  • 4 locations